Affluent Medical SA
EPA:AFME.PA
1.885 (EUR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.317 | 0.317 | 0.295 | 0.295 | 0.317 | 0.317 | 0.353 | 0.353 | 0.428 | 0.428 | 0.298 | 0.298 | 0.234 | 0.234 | 0.179 | 0.179 |
| Cost of Revenue
| 1.207 | 0.478 | 1.206 | 0.589 | 1.219 | 0.527 | 1.231 | 0.811 | 1.244 | 0.648 | 1.176 | 0.723 | 0.842 | 0.842 | 0.788 | 0.788 |
| Gross Profit
| -0.89 | -0.161 | -0.911 | -0.294 | -0.902 | -0.21 | -0.879 | -0.459 | -0.817 | -0.221 | -0.878 | -0.425 | -0.609 | -0.609 | -0.61 | -0.61 |
| Gross Profit Ratio
| -2.808 | -0.506 | -3.088 | -0.995 | -2.845 | -0.662 | -2.492 | -1.301 | -1.91 | -0.516 | -2.946 | -1.424 | -2.606 | -2.606 | -3.415 | -3.415 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 7.404 | 3.212 | 6.836 | 2.817 | 6.316 | 2.62 | 6.86 | 2.613 | 5.391 | 2.025 | 5.851 | 2.792 | 2.122 | 2.122 | 1.921 | 1.921 |
| Selling & Marketing Expenses
| 0.014 | 0.026 | 0.026 | 0.026 | 0.029 | 0.029 | 0.012 | 0.012 | 0.019 | 0.019 | 0.004 | 0.004 | 0.005 | 0.005 | 0.006 | 0.006 |
| SG&A
| 7.429 | 3.237 | 6.861 | 2.842 | 6.345 | 2.649 | 6.871 | 2.625 | 5.41 | 2.044 | 5.854 | 2.795 | 2.126 | 2.126 | 1.927 | 1.927 |
| Other Expenses
| -0.048 | 0 | -0.049 | 0 | -0.039 | 0 | 0.073 | 0 | -0.121 | 0 | 0.256 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 7.477 | 3.851 | 6.91 | 3.397 | 6.384 | 3.265 | 6.798 | 3.235 | 5.531 | 2.719 | 5.598 | 2.747 | 2.634 | 2.634 | 2.347 | 2.347 |
| Operating Income
| -8.684 | -3.987 | -8.116 | -3.713 | -7.603 | -3.477 | -8.029 | -3.718 | -6.775 | -2.92 | -6.774 | -3.756 | -3.265 | -3.265 | -2.97 | -2.97 |
| Operating Income Ratio
| -27.394 | -12.576 | -27.512 | -12.585 | -23.984 | -10.967 | -22.777 | -10.548 | -15.848 | -6.829 | -22.732 | -12.604 | -13.983 | -13.983 | -16.636 | -16.636 |
| Total Other Income Expenses Net
| 0.314 | 0.114 | -0.524 | -0.317 | -0.149 | -0.085 | -0.944 | -0.42 | -1.516 | -0.853 | -1.279 | -0.101 | -0.416 | -0.416 | -0.614 | -0.614 |
| Income Before Tax
| -8.37 | -3.873 | -8.64 | -4.029 | -7.752 | -3.562 | -8.973 | -4.138 | -8.291 | -3.772 | -8.053 | -3.857 | -3.681 | -3.681 | -3.584 | -3.584 |
| Income Before Tax Ratio
| -26.404 | -12.216 | -29.288 | -13.658 | -24.454 | -11.235 | -25.455 | -11.74 | -19.394 | -8.823 | -27.023 | -12.941 | -15.762 | -15.762 | -20.076 | -20.076 |
| Income Tax Expense
| -0.697 | 0.036 | -0.66 | 0.039 | -0.717 | 0.044 | -0.781 | 0.043 | -1.081 | 0.167 | -0.457 | 0.052 | 0.047 | 0.047 | 0.058 | 0.058 |
| Net Income
| -7.673 | -3.837 | -7.98 | -3.99 | -7.035 | -3.518 | -8.192 | -4.096 | -7.21 | -3.605 | -7.61 | -3.805 | -3.634 | -3.634 | -3.526 | -3.526 |
| Net Income Ratio
| -24.205 | -12.103 | -27.051 | -13.525 | -22.192 | -11.096 | -23.24 | -11.62 | -16.865 | -8.433 | -25.537 | -12.768 | -15.561 | -15.561 | -19.754 | -19.754 |
| EPS
| -0.25 | -0.13 | -0.29 | -0.15 | -0.36 | -0.18 | -0.44 | -0.23 | -0.39 | -0.2 | -0.41 | -0.24 | -0.25 | -0.25 | -0.29 | -0.29 |
| EPS Diluted
| -0.25 | -0.13 | -0.29 | -0.15 | -0.36 | -0.18 | -0.44 | -0.23 | -0.39 | -0.2 | -0.41 | -0.24 | -0.25 | -0.25 | -0.29 | -0.29 |
| EBITDA
| -7.477 | -3.294 | -6.91 | -3.199 | -6.384 | -2.97 | -6.798 | -3.196 | -5.531 | -2.4 | -5.598 | -3.229 | -2.958 | -2.958 | -2.453 | -2.453 |
| EBITDA Ratio
| -23.587 | -10.39 | -23.424 | -10.844 | -20.139 | -9.368 | -19.285 | -9.067 | -12.938 | -5.613 | -18.785 | -10.836 | -12.666 | -12.666 | -13.739 | -13.739 |